Details of Drug-Drug Interaction
| Drug General Information (ID: DDIY9G20CM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Fingolimod | Drug Info | Smallpox (Vaccinia) Vaccine, Live | Drug Info | |||||
| Drug Type | Small molecule | Vaccine | |||||||
| Therapeutic Class | Selective Immunosuppressants | Vaccine | |||||||
| Mechanism of Fingolimod-Smallpox (Vaccinia) Vaccine, Live Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Fingolimod | Smallpox (Vaccinia) Vaccine, Live | |||||||
| Mechanism | Immunosuppressive effects | Vaccine or toxoid | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Vaccine/toxoid | ||||||||
| Factor Description | The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy including fingolimod. Vaccination should be avoided during and for two months after treatment with fingolimod. In patients who have recently been vaccinated, fingolimod therapy should be postponed for one month to allow the full effect of vaccination to occur. Household contacts of immunosuppressed patients should also not be vaccinated. However, there are no absolute contraindications to vaccination if a high-risk exposure has occurred. In an outbreak emergency, smallpox vaccine is recommended for all persons, regardless of medical conditions. The risk for experiencing serious complications from the vaccine should be weighed against the risk of acquiring a potentially fatal smallpox infection. | ||||||||